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Expert’s summary:  
Filson et al. performed a prospective trial comparing targeted and systematic 
prostate biopsies performed with a multiparametric magnetic resonance imaging 
(mpMRI)-ultrasound-guided fusion biopsy system (Artemis, Eigen, Grass Valley, 
USA). A total of 1042 men underwent mpMRI imaging followed by a fusion image-
guided 12-core systematic biopsy. Men with suspicious lesions on mpMRI underwent 
additional targeted biopsies. A normal mpMRI was found in 217 patients (21%) with 
35 (16%) of them being diagnosed with a clinically significant (cs) prostate cancer 
(PCa) (e.g. Gleason score [GS] >=7) detected by systematic biopsy only. Among 825 
patients with a positive mpMRI a combination of targeted and systematic biopsy 
identified 289 cases of csPCa. Adding systematic biopsy to targeted biopsy resulted 
in 60 (7%) additional csPCa diagnoses, 15 (2%) additional high-risk (e.g. GS of >=8) 
PCa cases, and 73 (9%) additional GS 6 cases that would have otherwise been 
undiagnosed if only mpMRI detected lesions were targeted.  Thus, the number 
needed to biopsy with the combined approach to identify 1 additional case of csPCa 
was 14.  
 
Expert’s Opinion: Systematic transrectal ultrasound guided free-hand biopsy of the 
prostate has been the standard diagnostic tool in men suspected of PCa. The 
introduction of mpMRI now allows imaging-based detection and localization of 
tumours in the prostate. In a recent systematic review and meta-analysis, a targeted 
biopsy of such a lesion showed a higher rate of detection of csPCa compared with 
conventional systematic transrectal ultrasound guided free-hand biopsies[1]. 
However, the significance and extent of combined systematic biopsies remains 
controversial.  
Siddiqui et al. detected after adding systematic to targeted biopsy in their cohort of 
1003 patients with a positive mpMRI 29 (2.9%) additional csPCa cases [2]. That 
resulted in the significantly higher number of 35 patients needed to be biopsied 
additionally with the systematic approach to detect one csPCa case. The authors of 
the study performed a 12 core transrectal ultrasound guided free-hand biopsy. 
Consequently, the significantly lower performance of the systematic biopsy should 
have been anticipated. A more extended biopsy approach was followed by Radtke et 
al.[3]; in their study a transperineal template saturation biopsy (median 24 cores) was 
combined with MRI-ultrasound fusion guided targeted biopsy and lead to detection of 
11 (7%) additional cases of csPCa (a total of 153 patients with a PIRADS score >=3). 
A PIRADS score of <3 on mpMRI was present in 141 patients (48%) with 17 (12%) of 
them being diagnosed with a csPCa detected by systematic biopsy. Three important 
conclusions can be drawn from the present and the two cited prospective studies: 
First, a meaningful number of patients with negative mpMRI harboured csPCa which 
were only diagnosed by a systematic biopsy. Second, targeted biopsy alone would 
miss a relevant number of cs tumours and therefore should be combined with a 
systematic biopsy technique. And third, systematic biopsies should be performed 
either transperineally using a template grid or transrectally using an image-guidance 
system in order to ensure optimal spacing and maximal coverage of the gland. The 
number of additional cores should be based on the size of the gland and is still under 
debate. 
 
Unlike in many other solid tumors for which imaging and targeted biopsy is common, 
high false-negative rates or misgrading of the tumour through transrectal ultrasound 
guided free-hand biopsies has been a widely accepted issue for urologists for many 
years. Some of them still argue that a more extensive biopsy technique bears the risk 
of over detection of indolent tumours. However, since more than 50 years urologists 
are trying to answer the question, which patient should be treated and which 
therapeutic modality should be offered, using studies which are based on a 
diagnostic procedure with a low accuracy and reliability. With the introduction of 
active surveillance, focal / brachy / radio therapy and radical prostatectomy with 
nerve-sparing techniques, we owe our patients the best diagnostic evaluation 
technically possible and available. We should avoid repeating the mistakes of the 
past by compromising the diagnostic accuracy in favour of theoretical considerations 
of over detection or economic issues.   
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